Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
BMC Cancer2021Vol. 21(1), pp. 193–193
Citations Over TimeTop 10% of 2021 papers
Luiz H. Araujo, Bianca Mendes Souza, Laura Rabelo Leite, Sabrina A. F. Parma, Natália P. Lopes, Frederico Scott Varella Malta, Maíra Cristina Menezes Freire
Abstract
KRAS G12C presents in frequencies higher than several other driver mutations, and may represent a large volume of patients in absolute numbers. KRAS testing should be considered in all CRC and NSCLC patients, independently of clinical or demographic characteristics.
Related Papers
- → Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).(2013)43 cited
- → Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma(2012)24 cited
- → RAS status in Korean patients with stage III and IV colorectal cancer(2015)7 cited
- → RAS mutations distribution in a 108 patients series of colorectal cancer(2014)
- → KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan: Molecular spectrum, frequency and distribution pattern(2019)